The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.

Abstract

BACKGROUND:

Peritoneal dissemination is a critical prognostic factor in ovarian cancer. Although stabilized spheroid formation promotes cancer cell peritoneal dissemination in ovarian cancer, the associated oncogenes are unknown. In this study, we assessed the role of the KRAS oncogene in ovarian cancer cell dissemination, focusing on the stability of cells in spheroid condition, as well as the modulation of intracellular signaling following spheroid transformation.

METHODS:

We used ID8, a murine ovarian cancer cell line, and ID8-KRAS, an oncogenic KRAS (G12 V)-transduced ID8 cell line in this study. Spheroid-forming (3D) culture and cell proliferation assays were performed to evaluate the growth characteristics of these cells. cDNA microarray analysis was performed to identify genes involved in KRAS-associated signal transduction in floating condition. A MEK inhibitor was used to evaluate the effect on cancer peritoneal dissemination.

RESULTS:

Cell viability and proliferation in monolayer (2D) cultures did not differ between ID8 and ID8-KRAS cells. However, the proportions of viable and proliferating ID8-KRAS cells in 3D culture were approximately 2-fold and 5-fold higher than that of ID8, respectively. Spheroid-formation was increased in ID8-KRAS cells. Analysis of peritoneal floating cells obtained from mice intra-peritoneally injected with cancer cells revealed that the proportion of proliferating cancer cells was approximately 2-fold higher with ID8-KRAS than with ID8 cells. Comprehensive cDNA microarray analysis revealed that pathways related to cell proliferation, and cell cycle checkpoint and regulation were upregulated specifically in ID8-KRAS cells in 3D culture, and that some genes partially regulated by the MEK-ERK pathway were upregulated only in ID8-KRAS cells in 3D culture. Furthermore, a MEK inhibitor, trametinib, suppressed spheroid formation in 3D culture of ID8-KRAS cells, although trametinib did not affect 2D-culture cell proliferation. Finally, we demonstrated that trametinib dramatically improved the prognosis for mice with ID8-KRAS tumors in an in vivo mouse model.

CONCLUSIONS:

Our data indicated that KRAS promoted ovarian cancer dissemination by stabilizing spheroid formation and that the MEK pathway is important for stabilized spheroid formation. Disruption of spheroid formation by a MEK inhibitor could be a therapeutic target for cancer peritoneal dissemination.

• Authors: Juri Ogishima, Ayumi Taguchi, Akira Kawata, Kei Kawana, Mitsuyo Yoshida, Yuki Yoshimatsu, Masakazu Sato, Hiroe Nakamura, Yoshiko Kawata, Akira Nishijima, Asaha Fujimoto, Kensuke Tomio, Katsuyuki Adachi, Takeshi Nagamatsu, Katsutoshi Oda, Tohru Kiyono, Yutaka Osuga, Tomoyuki Fujii
• Journal: BMC cancer (BMC Cancer) Vol. 18 Issue 1 Pg. 1201 (Dec 03 2018) ISSN: 1471-2407 [Electronic] England
• PMID: 30509235 (Publication Type: Journal Article)

Topics

• Animals
• Cell Culture Techniques (methods)
• Cell Line, Tumor
• Cell Proliferation (physiology)
• Female
• Genes, ras (physiology)
• Humans
• MAP Kinase Signaling System (physiology)
• Mice
• Mice, Inbred C57BL
• Ovarian Neoplasms (metabolism, pathology)
• Spheroids, Cellular (metabolism)